Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Glutamate receptor modulators

What are glutamate modulators? 

Antipsychotic medications predominantly target the dopamine neurotransmitter system, with some efficacy for alleviating the positive symptoms of schizophrenia. However, the persistence of negative and cognitive symptoms suggests that other mechanisms are also likely to be involved. The glutamate hypothesis of schizophrenia proposes that reduction of glutamatergic N-methyl-D-aspartate (NMDA) receptor function represents a primary neuropathology in schizophrenia. Therefore, glutamate receptor modulators have been suggested as an adjunctive therapy to standard antipsychotic treatments, when individuals have sub-optimal responses to treatment. The glutamate receptor modulators that have been trialed in schizophrenia are predominantly amino acids, and act on several different aspects of the glutamatergic neurotransmission system. Agents include glycine, D-serine, D-cycloserine, D-alanine, CX516, sarcosine, N-acetyl cysteine, and memantine. These agents have been studied for efficacy in improving symptom severity and cognitive function.

What is the evidence for glutamate modulators?

Moderate to high quality evidence shows small improvements in negative, positive, and total symptoms with adjunctive N-methyl-d-aspartate modulators. For negative symptoms, D-serine, N-acetyl-cysteine, and D-alanine were most effective. For positive symptoms, NMDA receptor modulators with non-clozapine adjuncts were most effective. For total symptoms, D-serine, glycine, N-acetyl-cysteine, sarcosine, and D-alanine were most effective.

For memantine, moderate to high quality evidence finds medium-sized improvements in total and negative symptoms, with no significant effects on positive symptoms or general psychopathology. Lower quality evidence suggests there may also be some improvement in cognitive symptoms with adjunctive memantine.

For minocycline, moderate to low quality evidence suggests a small benefit for overall and negative symptoms, with no benefit for positive or depressive symptoms.

Moderate to high quality evidence suggests no overall benefit of adjunctive N-methyl-d-aspartate receptor-enhancing agents for cognition, although it may be beneficial in people aged between 30 and 39 years, and when taking N-acetyl cysteine for working memory.

September 2020

Last updated at: 2:22 am, 30th September 2020
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.